Visceral leishmaniasis (VL) is associated with increased circulating levels of multiple pro-inflammatory cytokines and chemokines, including IL-12, IFNc, and TNFa, and elevated expression of IFNc mRNA in lesional tissue such as the spleen and bone marrow. However, an immunological feature of VL patients is that their peripheral blood mononuclear cells (PBMCs) typically fail to respond to stimulation with leishmanial antigen. Unexpectedly, it was recently shown that Leishmania specific IFNc, can readily be detected when a whole blood stimulation assay (WBA) is used. We sought to define the conditions that permit whole blood cells to respond to antigen stimulation, and clarify the biological role of the IFNc found to be released by cells from VL patients. CD4+ T cells were found to be crucial for and the main source of the IFNc production in Leishmania stimulated whole blood (WB) cultures. Complement, antibodies and red blood cells present in whole blood do not play a significant role in the IFNc response. The IFNc production was reduced by blockade of human leukocyte antigen (HLA)-DR, indicating that the response to leishmanial antigens observed in WB of active VL patients is a classical HLA-T cell receptor (TCR) driven reaction. Most importantly, blockade of IFNc in ex-vivo splenic aspirate cultures demonstrated that despite the progressive nature of their disease, the endogenous IFNc produced in patients with active VL serves to limit parasite growth.
Introduction
Visceral leishmaniasis is a chronic disease caused by the protozoan parasites Leishmania donovani and Leishmania infantum/chagasi. Leishmania are transmitted by the bite of phlebotomine sand flies, and replicate within macrophages of their mammalian hosts. In VL, the target organs are chiefly the liver and the spleen. The disease is characterized by prolonged fever, spleno-hepatomegaly, wasting, hypergammaglobulinemia, pancytopenia and almost always leads to death if left untreated.
Based on experimental models, acquired resistance against Leishmania infection requires the development of a Th1 type immune response, characterized by IL-12 production by antigen presenting cells (APC) and IFNc production by T cells [1, 2] . IFNc is a key effector cytokine required for activation of infected macrophages for killing (reviewed by Kima and Soong [3] ). Patients with active VL have depressed cell-mediated immune responses, reflected by the failure of their peripheral blood mononuclear cells (PBMCs) to proliferate and/or to produce IFNc in response to stimulation with Leishmania antigens, while their ability to respond to polyclonal stimulation or other antigens, such as the purified protein derivative of Mycobacterium tuberculosis (PPD), remains relatively intact [4, 5] . The absence of antigen specific responses is thought to underlie the disease progression. Paradoxically, the acute phase of VL is associated with elevated expression of IFNc mRNA in lesional tissue, such as the spleen and bone marrow, as well as increased circulating levels of multiple pro-inflammatory cytokines and chemokines, including IL-12, IFNc and TNFa [4, 6] . These results imply that the failure to respond to Leishmania antigen stimulation observed in VL patients is not due to a defect in the ability to mount protective Th1 responses per se, but rather to induction of suppressive factors, e.g. IL-10, resulting in unresponsiveness of infected macrophages to activation signals [7] .
Studying immunological aspects of human VL has been severely hampered by the inability to measure antigen specific responses, including IL-10, using PBMC. The discovery of antigen specific cytokine responses following stimulation of whole blood (WB) [8] showed that VL patients are not void of Leishmania specific IFNc responses, findings that could be reconciled with the elevated levels of IFNc mRNA and circulating cytokines detected in active VL patients. Subsequent studies reported that the whole blood assay (WBA) could also be used to detect antigen-specific IL-10 responses [9, 10] . Thus, the WBA has opened up new possibilities for research aimed at understanding immunological determinants of the disease [8, 9, 10, 11] .
We sought to define the requirements for IFNc production seen using the WBA, and determine if the IFNc had a biological function in patients with active VL. We show that CD4+ T cells produce Leishmania specific IFNc in WB cultures. The responses to stimulation with Leishmania antigen observed in WB cultures of active VL patients occurred in the absence of complement, antibodies or cytokines present in serum of VL patients. Employing a splenic aspirate (SA) culture technique, as previously described [11] , we show that IFNc neutralization promotes parasite growth in active VL cases ex-vivo. These findings demonstrate that the elevated levels of IFNc in patients with active VL serve to limit parasite replication and suggest that therapeutic administration of IFNc may still hold potential.
Materials and Methods

Study groups
All VL patients presented with clinical symptoms of kala-azar at the Kala-azar Medical Research Center (KAMRC), Muzaffarpur, Bihar, India, and were confirmed to be VL positive by detection of amastigotes in splenic aspirates and/or by detection of antibodies against the recombinant antigen, K39. Venous blood and/or splenic aspirates (SA) samples collected from 84 (33 female and 51 male) patients with active VL were included in this study. All patients were treated with Amphotericin B and eventually cured disease. Aggregate clinical data of active VL patients are presented in Table 1 .
Ethics statement
The use of human subjects followed recommendations outlined in the Helsinki declaration. Informed written consent was obtained from all participants and/or their legal guardian when under 18 years of age. All human samples were coded an analysed anonymously. Ethical approval (Dean/2008-09/314, Dean/ 2012-2013/89) was obtained from the ethical review board of Banaras Hindu University (BHU), Varanasi, India.
Stimulation of whole blood (WB)
Whole blood (WB) was cultured using a volume of 0.5-1 ml blood per culture condition in round bottom 5 ml polypropylene tubes. For stimulation the samples were treated with SLA (10 mg/ ml). Control samples were treated with PBS. In some assays PHA (10 mg/ml) or Staphylococcus enterotoxin B, SEB, (5 mg/ml) was used as positive controls (not shown). Samples were incubated for 37uC in the presence of 5% CO 2 for 24 hours if not otherwise indicated in figure text.
To block HLA-TCR interaction 20 mg/ml anti-HLA-DR, clone 243, or isotype control IgG2a, clone MOPC-173, both ultra-LEAF purified (BioLegend, US) were added to the cultures simultaneously with antigen.
Inactivation of complement and replacement of plasma
To test if complement, antibody and/or other proteins present in plasma, but removed during purification of PBMC, affected SLA induced IFNc production we replaced the plasma in the WB samples. In brief, total blood cells were pelleted by centrifugation (500 g, 10 minutes, 18uC), the plasma was removed and blood was washed twice with PBS. To determine if complement affected the response, the plasma was heat inactivated [12] at 56uC for 30 minutes and added back to the autologous sample to restore the original blood volume. Alternatively, the plasma was replaced with heat inactivated fetal calf serum (HI-FCS).
Depletion and isolation of cell subsets
To determine the effects of different cell populations on SLA induced IFNc production we used magnetic beads and columns designed for the isolation/depletion of CD4 and CD8 cell subsets from whole blood as per manufacturer protocol (Whole Blood Column kit, Milteny Biotec). To control for the effect and spontaneous uptake of magnetic beads [13] we used anti-FITC beads (Milteny Biotech) as control. Whole blood and whole blood depleted of the cell subsets of interest were subsequently stimulated as described above. In these assays the patient plasma was replaced with HI-FCS prior to incubation with whole blood beads.
Lysis of red blood cells (RBC)
The influence of RBC on SLA induced IFNc was tested by lysis of RBC. Briefly, the total blood cells were centrifuged (500 g, 10 minutes, 18uC), followed by removal of plasma (see above). The cell pellet was resuspended in 5 ml hypotonic saline (0.6% NaCl) solution/1 ml blood for 20-30 seconds to lyse RBC. To stop the lysis an equal volume of hypertonic solution (1.6% NaCl) was added. The tube was filled with PBS and the non-lysed cells were pelleted and resuspended in autologous plasma to reconstitute the original volume, and stimulated as described above.
Author Summary
Our research aims to understand the immune failure underlying progression of human visceral leishmaniasis (VL). A key immunological feature of VL patients is that their peripheral blood mononuclear cells (PBMCs) do not respond to stimulation with leishmanial antigen. Surprisingly, when employing a whole blood assay we discovered significant levels of IFNc in response to soluble Leishmania donovani antigen (WBA) in VL patients. We were interested to understand the relevance of the IFNc to the antiparasitic response. Animal models and in vitro studies have shown that IFNc is a key effector cytokine required for control of the infection, however, the role of endogenous IFNc in control of parasites in VL patients, has not been demonstrated. Our results show that CD4 cells were required for and were the source of Leishmania specific IFNc in WBA of VL patients. Optimal IFNc response required interaction with HLA-DR, supporting that VL is not due to an intrinsic Th1 response defect per se. The Leishmania driven IFNc appears to limit parasite growth in patients with active VL, since blockade of IFNc ex-vivo in splenic aspirate cultures enhanced parasite survival. This suggests that IFNc may have been prematurely dismissed as an adjunct therapy in treatment of VL.
Culture of splenic aspirate (SA) cells
Splenic needle aspirates were collected for diagnostic purposes before treatment of VL. Approximately 100 ml SA was obtained by fine needle biopsy, following preparation of smears for diagnostic purpose, the residual cells were placed directly in 1 ml RPMI supplemented with 10% heat-inactivated fetal calf serum (HI-FCS) 200 mM Streptomycin and 100 U/ ml penicillin (C-RPMI) and 5 U/ml heparin. Samples were transported to the laboratory at BHU maintaining a temperature of 4-8uC. All samples were processed within 24 h of collection. For stimulation, the SA divided into two equal parts and treated with SLA (10 mg/ml) as done for the in the WBA (described above).
For baseline quantification of amastigotes by limiting dilution, 150 ml SA suspension was directly plated in a 96-well and serially diluted by transfer of 50 ml SA onto biphasic medium of 50 ml blood agar overlaid by 100 ml of M199/C, as previously described [14] . The remaining SA suspension was seeded into 96 wellculture plates (250 ml/well). Monoclonal antibody against human IFN-c, clone 25723 (R&D Systems) or control IgG2b clone 20116 (R&D Systems) were each added to a final concentration of 20 mg/ ml. The SA was incubated for 3 days at 37uC in 5% CO 2 , the supernatants were collected for cytokine assessment and the removed volume replaced by C-M199 medium, prepared as previously described [15] . From the SA culture 150 ml was transferred into a 96-well plate for estimation of parasite load by limiting dilution as described above. The number of viable parasites was determined from the highest dilution at which promastigotes could be grown out after 7 to14 days of incubation at 25uC.
For comparison with the WB, SA suspension was divided in two parts, stimulated with SLA (10 mg/ml) or with PBS and incubated for 24 hours at 37uC in 5% CO 2 , where after the supernatant was collected for cytokine assessment.
Cytokine analysis
Following 24 hours of stimulation (if not otherwise indicated) IFNc and IL-10 were measured in culture supernatants by ELISA. ELISA was performed as per manufacture instruction. For detection of IFNc the ELISA Max Deluxe set (BioLegend) or the QuantiFeron kit (Cellestis, Australia) were used. IL-10 was measured using matched antibody pair kits from BD Pharmingen. All values calculated from standard curve over or equal to zero were considered in statistical analysis. Negative values were assigned the value zero.
Flow cytometry (FACS) assessment of intracellular cytokine
To determine the cellular source/s of cytokines in the WBA, the cultures were stimulated for 16-24 hours. To block cytokine secretion cultures were for the last 6-8 hours of stimulation treated with GolgiStop (BD Biosciences) according to manufactures instructions. Following lysis of RBC using BD RBC lysis buffer (BD Biosciences), cells were surface stained using combinations of FITC, PE and PerCP/PE-Cy5 conjugated antibodies directed to CD3 (Clone UCHT1), CD4 or CD8 (all from BD Biosciences). Surface stained cells were fixed and permeabilized using BD Cytofix/Cytoperm, as per manufactures instruction, washed in permeabilization buffer (BD) and stained for presence of intracellular IFNc and IL-10 using APC and PE conjugated antibodies (both from Pharmingen) respectively. Following intra cellular staining (ICS), samples were acquired on FACSort (BD Biosciences) and analyzed using CellQuest Pro (BD) or FlowJo (Treestar) software. Analysis was done on cells gated as viable lymphocytes based on their forward-side scatter. SEB (10 mg/ml) stimulated samples were used as positive control for ICS (not shown).
Statistical analyses
Statistical analyses were done using PRISM5 (GraphPad Software). Different treatments using the same donor samples were compared by the Wilcoxon signed rank test for paired samples. Correlation between results was determined using Spearman-test for non-parametric correlations. Differences with P-values,0.05 were considered as significant. Outliers (donors with extreme values in one or more of the test conditions) were removed from data sets after being defined as outlier using GraphPad on-line Grubb's test for outliers.
Results
Kinetics of Leishmania specific IFNc secretion in whole blood cultures of patients with active VL
The whole blood Quantiferon assay (WBA) was originally designed as a tool for diagnosis of tuberculosis, and detects cytokine (IFNc) concentrations in plasma supernatants after 16-24 hours of incubation with antigen. To determine the kinetics of the WB responses in VL patients we measured secreted cytokines in supernatants after 6 hours to five days of stimulation with soluble Leishmania antigen (SLA). The induction of IFNc was rapid and observed in supernatants already 6 hours after stimulation, reaching a plateau at 18-24 hours (Figure 1a, b) . Antigen-induced IFNc was not detected in WB cultures following 72 hours culture or more (figure 1b). We conclude that the IFNc response seen in the WB cultures is rapid and short lived. For practical reasons stimulation times of 24 hours were used in subsequent assays if not otherwise indicated. We further tested if antigens specific responses could be detected in short-term (24 hr) splenic aspirate (SA) cultures. In line with the observations made using the WBA, an increase in IFNc was observed in supernatants of 73% of SA cultures following stimulation with SLA, indicating that antigen specific cells are present at the site of infection ( figure 1c) . In contrast to the SLA stimulated WB cultures where IL-10 tended to be induced [9, 10] , IL-10 levels dropped in SA cultures following SLA stimulation (figure 1d).
The WB response was not affected by serum complement inactivation, replacement of autologous plasma, or red blood cell lysis
The immune system of patients with VL is highly activated. We considered the possibility that other blood cell or serum components that are removed in the process of PBMC purification could be required for the Leishmania specific WB response. To address the effect of plasma components we replaced the plasma with i) autologous heat-inactivated plasma, to determine the role of complement, or ii) heat inactivated fetal calf serum (HI-FCS), to remove antibodies, complement, or other serum factors such as cytokines that may be elevated in VL. To address if RBC were important, we lysed the RBC using hypotonic treatment. None of these treatments affected the net production of IFNc measured using the WBA (figure 2), indicating that complement, antibodies, cytokines, or RBC are not important for the observed SLA induced IFNc production in WB. Indeed, removal of autologous plasma with HI-FCS potentiated the SLA induced response (figure 2). The replacement of plasma with FCS was subsequently employed in some of the assays that followed.
CD4 T cells are the source of IFNc in the WB response to SLA in patients with active VL
Understanding the cellular source/s of IFNc in the WB is critical to our reinterpretation of the immunologic defects in kalaazar. To determine the cellular requirements for IFNc production we removed various subsets from whole blood of VL patients prior to stimulation with SLA. Removal of CD4 cells caused a substantial loss of SLA induced IFNc in WB cultures, while removal of CD8 cells had no effect (figure 3a). Blockade of HLA using a pan-HLA-DR antibody caused a significant loss of SLA induced IFNc (figure 3b). This suggests that the IFNc response induced by SLA stimulation depends on HLA-TCR interaction. Three out of the 12 patient samples in which the effect of HLA-DR blockade was evaluated had low IFNc responses to SLA (, 100 pg/ml). To confirm CD4 T cells as the source of IFNc in WB, we assessed intracellular IFNc by FACS. SLA induced IFNc was only observed in the CD3+ population (all events considered). Figure 3c shows that the IFNc is produced by CD3+CD4+ cells, while figure 3d shows that there is a strong correlation between the frequency of IFNc positive T cells (CD3+) and the IFNc measured in WB culture supernatants by ELISA. IFNc was not detected in the CD3+CD8+ population following SLA stimulation and almost all cells producing IFNc following SLA stimulation were CD3+ CD82 (not shown).
To test if neutrophils contributed to the IFNc responses CD15+ cells were removed using depletion beads, this caused a partial though significant loss of SLA induced IFNc (figure S1), which may indicate an involvement of neutrophils in the observed SLA response, but since CD15 can be expressed on other cells, i.e. monocyte, we cannot exclude that the effect seen is due to removal of these cells.
IL-10 can be induced in stimulated WB from VL patients, albeit at low levels. Removal of CD4 cells caused a small but significant reduction of the amount of detectable IL-10 in SLA stimulated WB (figure 3e), indicating that CD4+ and other cells are sources of antigen-specific IL-10 in VL patients. CD8 cells do not appear to contribute to SLA induced IL-10 response, and their removal caused a slight enhancement of this response (Figure 3e ). The source of SLA induced IL-10 could not be confirmed by intracellular staining as the number IL-10 positive cells was below the limit of reliable detection.
Endogenous IFNc limit parasite replication in the spleen of visceral leishmaniasis patients
In experimental models it is well established that IFNc mediates control of parasite replication [16] and that lack of IFNc signalling causes disease progression [17, 18] . The same protective function is assumed in humans, but the direct proof that IFNc controls parasite replication in human VL is lacking. To test if the endogenous IFNc, which we now know to be elevated during active disease, plays a role in parasite control, we treated ex-vivo SA cultures with neutralizing antibodies against human IFNc followed by assessment of parasite growth, as previously described in assays designed to test the function of endogenous IL-10 [11] . Following neutralization of IFNc, the parasite load in SA increased in 19/31 (61%), was unchanged in 8/31 (26%) and decreased in 4/31 (13%) samples (figure 4a). The IL-10 levels in the SA supernatants were not affected by neutralization of IFNc (figure 4b), suggesting that the inhibitory effect of IL-10 on parasite killing does not completely abolish the parasite-controlling effects of endogenous IFNc. The background levels of IFNc detectable in ex vivo SA cultures were significantly reduced when CD4 cells were removed (figure 4c), indicating that CD4 cells are needed for the splenic IFNc production.
Discussion
In the search for markers of L. donovani infection, epidemiological studies utilising a WBA revealed Leishmania specific IFNc responses, long considered absent, in patients with active VL [8] .
The goals of the current study were to validate the prior WBA results, to reveal the conditions required for SLA induced IFNc secretion by WB and to determine if the IFNc seen in patients with active disease functions to limit the infection.
Whole blood contains cell populations, proteins, lipids and sugars that are largely removed when PBMC are purified. To test if such components were required for the antigen specific response we deprived WB cultures of RBC, plasma and complement. We found that replacement of autologous plasma and RBC lysis had no effect on the SLA induced IFNc response. By contrast, removal of CD4+ cells revealed these cells to be the main source of antigen specific IFNc secretion in the WB cultures, a finding that was substantiated by direct intracellular staining. In line with previous observation CD8 T cells were not found to contribute to SLA responses in patients with active VL [19] .
Removal of CD15+ cells also reduced the IFNc levels detectable in the SLA stimulated WB. CD15 (Lewis X) is a carbohydrate adhesion molecule primarily expressed on mature neutrophils in blood, but is also present on a subset of monocytes [20] . The decline in IFNc levels following CD15 depletion may thus be explained by a reduction of APCs required for the T cell response, but could also imply that neutrophils contribute to the response. By contrast, Abebe et al. have proposed, based on the observation that VL patients have more CD15+ and higher content of arginase expressing CD15+ cells pre compared to post treatment patients or endemic controls, that neutrophils contribute to the unresponsiveness of VL PBMC [12] . Neutrophil inhibition of the antigenspecific IFNc response in VL patients is not supported by the data presented here, where a reduction in IFNc secretion by WB cells was observed following CD15 depletion.
The detection of IFNc responses in stimulated splenic aspirate cells (figure 1c) indicates that antigen specific and responsive cells are present at the site of infection. Depletion of CD4 cells from ex vivo SA cultures support these cells as the source of IFNc at the site of infection. In contrast to the WB, where IL-10 was also induced following SLA stimulation, IL-10 levels decreased in SA following SLA stimulation (figure 1d). More critically, we show that the endogenous IFNc produced by splenic cells is biologically active and served to limit parasite growth in the SA cultures from the majority of VL patients, as shown by the increase in parasite numbers after IFNc neutralization ex-vivo. The lack of effect of the IFNc neutralization on parasite growth observed in some samples can be attributed to the nature of the SA. The sampling is done blind and the aspirates may vary in red and white blood cell content as well as the extent of disruption of infected cells, resulting in extracellular amastigotes that will be unaffected by the level of IFNc released. The treatment with anti-IFNc-antibodies did not affect the IL-10 levels detected in the SA supernatants (figure 4), suggesting that the inhibitory effects of IFNc on parasite survival and growth occurs even in the presence of high levels of IL-10. The IFNc response we detect in active cases, while functional, is clearly not a sufficient condition for cure, as the patients would succumb to the disease without treatment. We propose that fragility and/or short life span of these cells may limit their ability to mediate a fully curative response, although other factors, in particular IL-10, are clearly involved [11] .
Our data suggest that even in untreated patients, their disease progression would be far worse in the absence of the endogenous IFNc that they produce. Notably, there are patients whose cellular responses cannot be detected even when using the WBA. While not directly reflected in the clinical parameters (i.e. blood chemistry), these patients may have progressed further in the disease and lost the responding population. It may be noted that there was a negative correlation between SLA induced IFNc response in WBA and parasite load in blood (Spearman r = 20.66; p = 0.004, n = 17), which indicates that the WB SLA response to a degree may reflect the severity of disease. Genetic or acquired defects in their ability to mount Th1 responses to Leishmania may also underlie the lack of response in some patients. We found that the SLA induced IFNc response involved HLA-DR interaction as treatment with HLA-DR blocking antibody reduced the IFNc levels in all donors tested (figure 3b), with an average decrease of 70% compared to control antibody treatment. The partial effect observed may be explained by utilization of HLA-DQ in the presentation of leishmanial antigens to T cells. While HLA-DR together with it's peptide is the classical ligand for T cells recognizing foreign antigens, HLA-DQ may also present peptides from pathogens and initiate T cells responses. The role of HLA molecules on WB SLA responses are of interest since risk alleles for development of VL were recently identified within in the MHC class II region [21] . The influence of allelic differences and role of different MHC molecules in the ability to drive Leishmania specific responses in the WB culture are under current investigation.
The functional Th1 response in active VL patients may also be highly relevant to their response to treatment. L. donovani infection in T cell deficient mice revealed a clear role for antigen specific T cells in the curative response to pentavalent antimony [22] . Our findings reinforce the rationale for the prior VL treatment trials carried out in the 1990s involving recombinant IFNc, indicating that monotherapy could be beneficial [23, 24] . The lack of response to monotherapy in some patients and the absence of a long-lasting therapeutic effect, as well as the limited success as adjunct therapy with sodium stibogluconate [25] , discouraged further trials. Our present and more recent studies suggest that antigen-specific IFNc production may in some patients not be the limiting factor in their non-curative response.
In summary, our data support the notion that disease progression in VL is not due to a complete failure in Th1 development. Our findings make clear that WB cultures may allow detection of functionally relevant immune responses not seen using PBMC. Most patients with VL have antigen specific CD4 T cells capable of secreting IFNc both in the blood and at the site of infection -the spleen. We further show that the IFNc produced by VL patients play a role in limiting parasite growth. 
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